In our Amp Patent Investor subscription forum, I provide my analysis of the possible affect on the appellate court's ruling, of the recent scientific publication by the Reduce-It trial's principal investigator, Dr. Bhatt (Curfman et al., "Federal Judge Invalidates Icosapent Ethyl Patents –But Based on a Common Statistical Mistake" (2020)) (Electronic copy available at: https://ssrn.com/abstract=3618671). This publication attacks the district court's ruling regarding the Mori prior art with statistical analysis. Sign up today (CLICK HERE) for our Patent Investor subscription and get my experienced patent attorney perspective on whether this unusual development is likely to affect the outcome of the appeal.
With this subscription, you get my ongoing insights into the appellate process so that you can use it to your advantage. There are important events that will occur with respect to the outcome of this appeal, some of which are not well understood or even known by investors. I will explain these to you so that you are not caught by surprise. This is must-have knowledge for investors and my passion and compassion for retail investors led me to make this available at a retail investor price point. Sign up today (CLICK HERE)